[Treatment of depression using MAO-A inhibitors: an open study of a direct switch from moclobemide to tri-/tetracyclic antidepressants].
In an open study 13 depressed inpatients received moclobemide, a selective and reversible MAO-A-inhibitor (300 mg/d) for one week and subsequently were switched to a three-week course of a tricyclic or tetracyclic antidepressant (TCA) without medication-free interval. There were no drop-out, two patients needed additional ECT. Depressive symptomatology declined during treatment which was well tolerated. Mild adverse CNS effects and gastrointestinal symptoms prevailed under moclobemide. Subsequent TCA prompted autonomic symptoms. Overall adverse drug effects decreased over the treatment period. Cardiovascular monitoring revealed no clinically relevant side effects.
Becker
T
T
Psychiatrische Universitätsklinik, Würzburg.
Struck
M
M
Laux
G
G
D000328:Adult; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects*; D001549:Benzamides / Q000008:administration & dosage / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020912:Moclobemide; D011569:Psychiatric Status Rating Scales
D000928:Antidepressive Agents; D000929:Antidepressive Agents, Tricyclic; D001549:Benzamides; D020912:Moclobemide
Depressionsbehandlung mit MAO-A-Inhibitoren: Offene Studie zur Direktumstellung von Moclobemid auf tri-/tetrazyklische Antidepressiva.